Otitis Media With Effusion Clinical Management: Monitoring, Treatment Pathways, and Escalation

Otitis Media With Effusion Clinical Management: Monitoring, Treatment Pathways, and Escalation

Middle ear effusion — also referred to as otitis media with effusion (OME), serous otitis media, or non-suppurative otitis media — is the accumulation of non-infected fluid in the middle ear space. It is the leading cause of conductive hearing loss in children and accounts for an estimated 2.2 million new diagnoses annually in the United States, with associated costs exceeding $4 billion. Despite its prevalence, OME is frequently underdiagnosed and undermanaged, particularly in infants and children who cannot describe their symptoms.

What clinical factors should shape OME follow-up?

OME follow-up should be shaped by the duration of effusion, laterality, documented hearing impact, the child’s developmental profile, and the presence of risk factors that alter the threshold for intervention.

Follow-up is not one-size-fits-all. A child with unilateral OME of recent onset, no documented hearing loss, and no developmental concerns warrants a different monitoring interval than a child with bilateral chronic OME, speech concerns, or a craniofacial condition affecting Eustachian tube function. The AAO-HNSF 2016 Clinical Practice Guideline on Otitis Media with Effusion identifies specific at-risk populations — including children with Down syndrome, cleft palate, autism spectrum disorder, permanent hearing loss, and sensory or cognitive developmental delays — for whom standard watchful waiting timelines do not apply and earlier evaluation is indicated regardless of effusion duration.

For children without risk factors and recent-onset effusion, an initial monitoring period of up to three months is appropriate, provided hearing is not significantly affected and the family can participate in surveillance. Bilateral effusion with documented hearing loss warrants more proactive follow-up and hearing assessment within this window. Unilateral effusion in an adult without a clear precipitating cause — cold, barotrauma, allergy — should prompt early ENT evaluation to exclude a nasopharyngeal mass.

How does OME persistence affect the clinical management pathway?

When middle ear effusion persists beyond three months, the management pathway shifts from observation to active decision-making — requiring formal hearing assessment, evaluation of developmental impact, and discussion of non-surgical and surgical options.

Acute OME — fluid present for fewer than three months — has a favorable natural history. The majority of episodes in otherwise healthy children resolve spontaneously within this window, which is why initial observation is guideline-endorsed. Once fluid crosses the three-month threshold, it is classified as chronic otitis media with effusion, and the probability of spontaneous resolution falls significantly. A meta-analysis (Rosenfeld & Kay, Laryngoscope 2003) found that chronic OME resolves in only approximately one in three children within a year without intervention.

Persistence changes the clinical calculus. The primary considerations at this stage are: whether bilateral hearing loss is documented, whether the child has developmental, speech, or language concerns attributable in part to the hearing deficit, and what the family’s preferences are regarding non-surgical management versus surgical referral. Clinicians should weigh the cumulative hearing burden, the child’s age and developmental window, and the availability of non-surgical options before determining the next step.

How should clinicians monitor OME before escalation?

OME monitoring before escalation should include regular otoscopic assessment, tympanometry to objectively evaluate middle ear pressure and eardrum mobility, and age-appropriate audiometry to document whether hearing loss is present and to what degree.

Pneumatic otoscopy remains the primary diagnostic tool for identifying middle ear effusion. Tympanometry provides an objective, non-invasive complement — a flat (type B) or negative-pressure (type C) tympanogram is consistent with middle ear fluid and does not require patient cooperation, making it reliable in young children. For children with bilateral OME and hearing concerns, the AAO-HNSF guideline recommends formal audiometric evaluation at or before three months of known effusion duration.

Follow-up intervals should be individualized. Children with fluctuating or worsening hearing, teacher and caregiver reports of communication difficulties, or emerging speech and language concerns warrant closer surveillance than those with stable, mild, or unilateral effusion. Caregiver observations gathered between appointments — reported listening difficulties, missed instructions, and communication changes — provide clinical context that a single office visit cannot capture.

For a detailed review of tympanometric findings, audiometric thresholds, and middle ear assessment in OME, see [Tympanometry, Hearing Assessment, and Middle Ear Findings in OME].

When should otitis media with effusion treatment move beyond observation?

‘
Otitis media with effusion treatment should move beyond observation when bilateral OME has persisted for three months or more with documented hearing loss, when OME of any duration is present in an at-risk child, or when the hearing deficit is causing a meaningful impact on a child’s development, communication, or quality of life.

The AAO-HNSF 2016 guideline recommends offering tympanostomy tube insertion — not prescribing it — when chronic bilateral OME is accompanied by documented hearing loss. This is a shared decision-making conversation, not an automatic escalation. Clinical indications for ENT referral include: bilateral OME persisting beyond three months with audiometric hearing loss; OME of any duration in a child with Down syndrome, cleft palate, or other identified at-risk conditions; and OME associated with significant speech, language, or developmental concerns.

Adenoidectomy may be considered concurrently in children four years of age and older with a separate indication such as nasal obstruction or recurrent adenoiditis, but is not indicated for OME alone as a first procedure in younger children. Tympanostomy tube insertion carries its own procedural discussion around general anesthesia, tube type, expected duration, otorrhea risk, follow-up, and the possibility of repeat insertion in approximately 14% of cases.

For a structured evaluation framework and clinical indications for surgical referral, see [When Should Pediatric OME Be Evaluated for Tympanostomy Tubes?]

Where do non-surgical options fit into OME treatment discussions?

Non-surgical options for OME — principally autoinflation of the Eustachian tube — are most relevant during the observation period, when families are weighing continued monitoring against escalation, and when the goal is to support middle ear ventilation without a procedure.

The AAO-HNSF 2016 Clinical Practice Guideline specifically endorses autoinflation of the Eustachian tube as a non-surgical intervention that may offer clinical benefit during the OME surveillance period. Autoinflation works by delivering positive nasopharyngeal pressure to encourage Eustachian tube opening, normalizing middle ear pressure, and promoting fluid clearance.

Device selection and technique matter clinically. Conventional autoinflation methods require the child to blow forcefully against nasal resistance — a technique that many children under five cannot perform reliably, that carries over-inflation risk, and that may cause discomfort. Caregiver guidance on technique and consistent use are important determinants of whether autoinflation produces a clinically meaningful result.

A practical consideration for clinicians: parents managing a child with OME often find the watchful waiting period difficult to accept, even when it is clinically appropriate. The absence of active treatment can feel like inaction, and many will present asking for antibiotics or a referral for tubes before the three-month threshold has been reached. Antibiotics are not indicated for OME without active infection, and escalation to surgery before the observation period is complete is rarely warranted. Swallow-coordinated autoinflation is a clinically meaningful response to this situation. It can be recommended as an active, evidence-based therapy at any point during monitoring — not only after three months — giving families something purposeful to do during the observation period while directly addressing the underlying pressure deficit. Framing it this way tends to reduce pressure on clinicians to prescribe antibiotics or accelerate surgical referral.

For a structured review of autoinflation evidence, device considerations, technique, and monitoring, see [Autoinflation as a Non-Surgical Option in Pediatric OME Management].

How does Earflo support clinician-led OME management?

Earflo is an FDA-cleared swallow-coordinated autoinflation device designed for use in the management of negative middle ear pressure and otitis media with effusion. It is available for both paediatric and adult patients, making it relevant across the range of OME presentations clinicians encounter.

The mechanism: Unlike conventional autoinflation approaches that deliver pressure against a closed Eustachian tube — requiring forceful blowing and carrying both aspiration risk and overpressurization risk — Earflo coordinates air delivery precisely during the natural opening of the Eustachian tube that occurs with every swallow. Because the tube is already in active dilation at the moment of delivery, pressure requirements are significantly lower, aspiration risk is eliminated, and the experience is comfortable for the patient.

Compliance and training tools: Consistent use is a known determinant of autoinflation outcomes. Earflo addresses this with two built-in feedback mechanisms: a light indicator that provides real-time confirmation of correct technique and successful swallow detection, and a companion app that tracks compliance and reinforces technique over time. These tools contributed to the 99% objective compliance rate observed across both published clinical studies — a figure that is substantially higher than compliance rates reported for conventional nasal balloon autoinflation in children (Webster et al., Cochrane 2023).

The evidence: Two published clinical studies (Soto et al., OTO Open 2025; Hura et al., American Journal of Otolaryngology 2026) evaluated Earflo in children with OME, including children who had already met criteria for tympanostomy tube placement. Across both studies: 99% compliance, an average 12.9–14.2 dB hearing improvement at two weeks, 91% tympanometric improvement during active use, 89% avoided tympanostomy tube surgery, and no adverse events were reported.

Clinical positioning: For clinicians discussing OME management pathways with families, Earflo provides a guideline-endorsed, non-surgical option that can be initiated during watchful waiting, used alongside surveillance, and offered as an alternative or complement to surgical escalation in appropriate patients. For adult patients with negative middle ear pressure, Eustachian tube dysfunction, or OME — where the surgical threshold discussion differs from paediatric practice — Earflo offers the same swallow-coordinated mechanism with the same training and feedback tools.

Earflo does not replace clinical monitoring, audiometric assessment, or surgical evaluation when those are indicated. It occupies the treatment space between watchful waiting and surgery, providing active management during the observation period.

Key takeaways

OME follow-up is individualized — duration, laterality, hearing status, and developmental risk all shape monitoring intervals and the threshold for escalation
Chronic OME — fluid present for three months or more — warrants formal hearing assessment and active discussion of management options; spontaneous resolution occurs in only approximately one in three children within a year at this stage
Monitoring should combine pneumatic otoscopy, tympanometry, and age-appropriate audiometry; caregiver observations between appointments provide clinical context a single visit cannot capture
Otitis media with effusion treatment moves beyond observation when bilateral chronic OME is accompanied by documented hearing loss, when at-risk children are involved, or when developmental or communication impact is significant
Autoinflation is the non-surgical intervention the AAO-HNSF guideline endorses during OME surveillance; device selection and technique affect clinical utility
Earflo’s swallow-coordinated mechanism eliminates aspiration risk, operates at lower pressure than conventional devices, and causes no discomfort; built-in light feedback and a companion app support technique and compliance; two published clinical studies confirm 99% compliance and 89% surgery avoidance

Learn more about Earflo for clinicians →

About the Author

Dr. Peter Santa Maria, MD, PhD Professor & Division Chief of Otology and Neurotology Vice Chair of Translational and Clinical Research, University of Pittsburgh

Dr. Santa Maria is an ear surgeon-scientist specializing in advanced ear disease, hearing loss, and Eustachian tube disorders. He is the principal investigator of the two published clinical studies on swallow-coordinated autoinflation cited in this article, and co-founder and Chief Medical Officer of Earflo, Inc.

Disclosure: Dr. Santa Maria is a co-inventor of Earflo and holds equity in the company.

References

Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical Practice Guideline: Otitis Media with Effusion (Update). Otolaryngology–Head and Neck Surgery. 2016;154(1 Suppl):S1–S41.
Rosenfeld RM, Tunkel DE, Schwartz SR, et al. Clinical Practice Guideline: Tympanostomy Tubes in Children (Update). Otolaryngology–Head and Neck Surgery. 2022;166(1_suppl):S1–S55. doi:10.1177/01945998211065662.
Rosenfeld RM, Kay D. Natural history of untreated otitis media. Laryngoscope. 2003;113(10):1645–1657. doi:10.1097/00005537-200310000-00004. PMID: 14520089.
Soto MJ, Hura N, Oldakowska I, Oldakowski M, Bumbak P, Santa Maria PL. Feasibility of a Novel Autoinflation Device to Treat Pediatric Otitis Media With Effusion At-Home. OTO Open. 2025;9(2):e70128. doi:10.1002/oto2.70128. PMID: 40370996.
Hura N, Soto MJ, Lalwani Z, Oldakowska I, Oldakowski M, Bumbak P, Santa Maria PL. A novel autoinflation device for persistent pediatric otitis media with effusion: A prospective single-arm cohort study. American Journal of Otolaryngology. 2026;47(4):104862. doi:10.1016/j.amjoto.2026.104862. PMID: 42296786.
Webster KE, Mulvaney CA, Galbraith K, Rana M, Marom T, Daniel M, Venekamp RP, Schilder AGM, MacKeith S. Autoinflation for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews. 2023;(9):CD015253. doi:10.1002/14651858.CD015253.pub2. PMID: 37750500.
Mârțu C, Cozma S, Cobzeanu B, et al. Serous otitis media: Clinical and therapeutic considerations, including dexamethasone intratympanic injection. Experimental and Therapeutic Medicine. 2022;23(2):125. doi:10.3892/etm.2021.11048. PMID: 34970348.
Ashoor A. Middle Ear Effusion in Children: Review of Recent Literature. Journal of Family & Community Medicine. 1994;1(1):12–18. PMID: 23008530. PMC: PMC3437176.
National Institute for Health and Care Excellence. Otitis media with effusion in under 12s (NG233). August 2023.